1. Home
  2. RCEL vs NYXH Comparison

RCEL vs NYXH Comparison

Compare RCEL & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$8.12

Market Cap

146.2M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$1.61

Market Cap

161.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCEL
NYXH
Founded
N/A
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.2M
161.9M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
RCEL
NYXH
Price
$8.12
$1.61
Analyst Decision
Buy
Strong Buy
Analyst Count
5
3
Target Price
$7.88
$9.33
AVG Volume (30 Days)
571.9K
129.0K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
27.20
N/A
EPS
N/A
N/A
Revenue
$71,610,000.00
N/A
Revenue This Year
$17.17
$213.98
Revenue Next Year
$49.82
$126.25
P/E Ratio
N/A
N/A
Revenue Growth
11.45
N/A
52 Week Low
$3.22
$1.26
52 Week High
$8.35
$6.95

Technical Indicators

Market Signals
Indicator
RCEL
NYXH
Relative Strength Index (RSI) 79.06 53.71
Support Level $3.62 $1.26
Resistance Level N/A $1.70
Average True Range (ATR) 0.51 0.06
MACD 0.37 0.04
Stochastic Oscillator 93.18 98.39

Price Performance

Historical Comparison
RCEL
NYXH

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: